McEnany Patrick J's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Nov 21, 2024
- Accession no.
- 0001161697-24-000457
- Filed
- Nov 21, 2024
- Trade date
- Nov 19-20, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.63M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McEnany Patrick JCIK 0000929985 | Director, Other: Chairman of Board of Directors |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +98,345 | $3.54 | +$348,141.3 | 4,576,514 | Direct | |
| Nov 19, 2024 | Common stock, par value $0.001 per share | SSaleDisposed | −98,345 | $21.19F2 | −$2,083,930.55 | 4,478,169 | Direct | |
| Nov 20, 2024 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +72,500 | $3.54 | +$256,650 | 4,550,669 | Direct | |
| Nov 20, 2024 | Common stock, par value $0.001 per share | SSaleDisposed | −72,500 | $21.29F3 | −$1,543,525 | 4,478,169 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 | Common Stock | MOption exerciseDisposed | −98,345 | $0.00 | $0 | 1,865,245 | Direct | |
| Nov 20, 2024 | Common Stock | MOption exerciseDisposed | −72,500 | $0.00 | $0 | 1,792,745 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.11 to $21.31 per share.
Referenced by the price of 1 transaction in Table I.
- F3
Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.05 to $21.455 per share.
Referenced by the price of 1 transaction in Table I.